The effect of nicotine on perceptual, ocular motor, postural, and vegetative functions at rest and in motion.
Nicotine has wellknown, unpleasant side effects, e.g., transient dizziness, nausea, and nicotine-induced nystagmus (NIN). To investigate factors influencing these effects, we addressed three questions: (1) Is the intensity of dizziness, nausea, NIN, and unsteadiness dependent on nicotine dosage? (2) Does the intensity of perceptual, ocular motor, vegetative effects, and postural imbalance correlate? (3) Do visual or vestibular motion stimuli produce and/or aggravate distressing dizziness and nausea? Sixty healthy non-smokers or occasional smokers participated; 40 were tested once before and six times after application of a nicotine nasal spray in doses of 1 mg or 2 mg with or without motion stimulation; 20 received a placebo nasal spray. Plasma nicotine concentrations were significantly related to nicotine dosage. Dizziness, nausea, NIN, and unsteadiness also depended on the nicotine dosage (p < 0.01).Nicotine blood concentration was a better predictor for the temporal dependence of nystagmus than nicotine dosage. Dizziness correlated highly with nausea (R = 0.63, p < 0.001). The degree of nicotine-induced nausea significantly correlated with postural imbalance. The time course of postural sway differed according to nicotine dosage and gender: for women, there was no clear relationship between sway magnitude and nicotine dosage, while men showed increased sway with higher dosage. Motion stimulation increased nicotine-induced dizziness and nausea, but did not significantly influence NIN or postural imbalance. Our data support the view that all measured adverse effects reflect dose-dependent nicotine-induced vestibular dysfunction. Additional motion stimulation aggravates dizziness and nausea, i.e., nicotine increases sensitivity to motion sickness.
Zingler
V C
VC
Dept. of Neurology, Ludwig-Maximilians University, Klinikum Grosshadern, Marchioninistrasse 15, 81377, Munich, Germany. vzingler@med.uni-muenchen.de
Denecke
K
K
Jahn
K
K
von Meyer
L
L
Krafczyk
S
S
Krams
M
M
Elfont
R
R
Brandt
T
T
Strupp
M
M
Glasauer
S
S
D000281:Administration, Intranasal; D000328:Adult; D000704:Analysis of Variance; D004244:Dizziness / Q000139:chemically induced / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009038:Motion; D009325:Nausea / Q000139:chemically induced / Q000503:physiopathology; D009538:Nicotine / Q000008:administration & dosage* / Q000097:blood; D018722:Nicotinic Agonists / Q000008:administration & dosage* / Q000097:blood; D017120:Nystagmus, Optokinetic / Q000187:drug effects; D010468:Perceptual Disorders / Q000139:chemically induced / Q000503:physiopathology; D011187:Posture / Q000502:physiology; D011897:Random Allocation; D012146:Rest; D012678:Sensation Disorders / Q000139:chemically induced / Q000503:physiopathology; D015837:Vestibular Diseases / Q000139:chemically induced / Q000503:physiopathology
D018722:Nicotinic Agonists; D009538:Nicotine